ZOSTAVAX(R) Local Registration Trial (V211-019)

PHASE3CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Varicella Virus Infection

Interventions

BIOLOGICAL

Zoster Vaccine, Live, (Oka-Merck)

A single dose of 0.65 ml of Zostavax injection was given to each study subject

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00444860 - ZOSTAVAX(R) Local Registration Trial (V211-019) | Biotech Hunter | Biotech Hunter